Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells

Biotechnology Journal

Volumn 4, Issue 2, 2009, Pages 186-201

  Grillberger, Leopold ^a   Kreil, Thomas R ^a   Nasr, Sonia ^b   Reiter, Manfred ^a,c  

^a BAXTER BIOSCIENCE   (Austria)

^b Therapy Management Specialists Inc   (United States)

^c BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Animal free; Biopharmaceutical manufacturing; Emerging pathogen; Recombinant therapeutic protein; Serum free

Indexed keywords

ANIMAL-FREE; BIOPHARMACEUTICAL MANUFACTURING; EMERGING PATHOGEN; RECOMBINANT THERAPEUTIC PROTEIN; SERUM-FREE;

BODY FLUIDS; CELL CULTURE; LIGANDS; MAMMALS; MANUFACTURE; PATHOGENS; PLASMAS; PROTEINS;

ANIMAL CELL CULTURE;

ADALIMUMAB; ALTEPLASE; ANTICOAGULANT AGENT; BETA1A INTERFERON; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR CONCENTRATE; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ECULIZUMAB; GONADOTROPIN DERIVATIVE; HUMAN SERUM ALBUMIN; INFLIXIMAB; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GROWTH HORMONE; RECOMBINANT HUMAN INSULIN; RECOMBINANT PROTEIN; RECOMBINANT SOMATOMEDIN; RECOMBINANT TRANSFERRIN; REMICADECENTO; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; BLOOD DONOR; BLOOD TRANSFUSION; BLOODSTREAM INFECTION; BOVINE SPONGIFORM ENCEPHALOPATHY; CLINICAL TRIAL; DRUG CONTAMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PURIFICATION; DRUG QUALITY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENTERITIS; FOOD CONTAMINATION; HEMOPHILIA; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION RISK; MAMMAL CELL; MULTIPLE SCLEROSIS; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEVERE ACUTE RESPIRATORY SYNDROME; VARIANT CREUTZFELDT JAKOB DISEASE; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; BIOSYNTHESIS; CULTURE MEDIUM; DRUG DESIGN; EUKARYOTIC CELL; MAMMAL; PHARMACEUTICS; PHYSIOLOGY; PROTEIN ENGINEERING;

ANIMALIA; HEPATITIS C VIRUS; MAMMALIA;

ANIMALS; CULTURE MEDIA, SERUM-FREE; DRUG DESIGN; EUKARYOTIC CELLS; HUMANS; MAMMALS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 64349114245     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200800241     Document Type: Review

References (88)

1. Walsh, G., Biopharmaceutical benchmarks. Nature Biotech. 2006, 24, 769-776.
2. Dingermann, T., Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J. 2008, 3, 90-97.
3. Wurm, F. M., Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotech. 2004, 22, 1393-1398.
4. Mohan, C., Kim, Y. G., Koo, J., Lee, G. M., Assessment of cell engineering strategies for improved therapeutic protein production in CHO cells. Biotechnol J. 2008, 3, 624-630.
5. Gerngross, T.U., Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nature Biotech. 2004, 22, 1409-1414.
6. Shapiro, A. D., Anti-hemophilic factor (recombinant), plasma/ albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. Vasc Health Risk Manag. 2007, 3, 555-565.
7. Ewenstein, B. M., Collins, P., Tarantino, M. D., Negrier, C. et al., Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol. 2004, 41(1 Suppl 2), 1-16.
8. Dodd, R. Y., Leiby, D. A., Emerging infectious threats to the blood supply. Annu Rev Med. 2004, 55, 191-207.
9. Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L. et al., Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302, 276-278.
10. Hino, S., TTV, a new human virus with single stranded circular DNA genome. Rev Med Virol. 2002, 12, 151-158.
11. Hilgartner, M.W., The need for recombinant factor VIII: historical background and rationale. Semin Hematol. 1991, 28(2 suppl 1), 6-9.
12. Ludlam, C. A., Powderly, W. G., Bozzette, S., Diamond, M. et al., Clinical perspectives of emerging pathogens in bleeding disorders. Lancet. 2006, 367, 252-261.
13. Schneider, B., Fryer, J. F., Oldenburg, J., Brackmann, H. H. et al., Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia 2008 Jun 18.
14. Fryer, J. F., Hubbard, A. R., Baylis, S. A., Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang. 2007, 93, 341-347.
15. Soucie, J. M., Siwak, E.B., Hooper, W.C., Evatt, B. L. et al., Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion 2004, 44, 1179-1185.
16. Gaboulaud, V., Parquet, A., Tahiri, C., Claeyssens, S. et al., Suivi Thérapeutique National des Hémophiles Group. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Br J Haematol. 2002, 116, 383-389.
17. Toole J. J., Knopf, J. L., Wozney, J. M., Sultzman, L. A. et al., Molecular cloning of a cDNA encoding human antihaemophilic factor. 1984. Biotechnology 1992, 24, 310-315.
18. Vehar, G.A., Keyt, B., Eaton, D., Rodriguez, H et al., Structure of human factor VIII. Nature 1984, 312, 337-342.
19. Aygoren-Pursun, E., Scharrer, I., A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb Haemost. 1997, 78, 1352-1356.
20. Tarantino, M.D., Collins, P.W., Hay, C. R., Shapiro, A.D. et al., rAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004, 10, 428-437.
21. Dollard, S. C., Nelson, K. E., Ness, P. M., Stambolis, V. et al., Possible transmission of human herpesvirus-8 by blood transfusion in a historical United States cohort. Transfusion 2005; 45, 500-503.
22. Hladik, W., Dollard, S. C., Mermin, J., Fowlkes, A. L. et al., Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. 2006, 355, 1331-1338.
23. Chamberland, M., Khabbaz, R. F., Emerging issues in blood safety. Infect Dis Clin North Am. 1998, 12, 217?229.
24. Chamberland, M. E., Alter, H. J., Busch, M. P., Nemo, G. et al., Emerging infectious disease issues in blood safety. Emerg. Infect. Dis. 2001, 7, 552-553.
25. Hill, A. F., Zeidler, M., Ironside, J., Collinge, J., Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997, 349, 99-100.
26. Llewelyn, C. A., Hewitt, P. E., Knight, R. S. G., Amar, K. et al., Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004, 363, 417-421.
27. Peden, A. H., Head, M.W., Ritchie, D. L., Bell, J. E. et al., Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004, 364, 527-529.
28. Ironside, J.W., Head, M.W., Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 2004, 10 (Suppl 4), 64-69.
29. Houston, F., McCutcheon, S., Goldmann, W., Chong, A. et al., Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008, Jul 22
30. Ludlam, C. A., Turner, M. L., Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol. 2006, 132, 13-24.
31. Collinge, J., Whitfield, J., McKintosh, E., Beck, J. et al., Kuru in the 21st century - an acquired human prion disease with very long incubation periods. Lancet 2006, 367, 2068-2074.
32. Cochius, J. I., Hyman, N., Esiri, M. M., Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin: a second case. J Neurol Neurosurg Psychiatry 1992, 55, 1094-1095.
33. Swerdlow, A. J., Higgins, C. D., Adlard, P., Jones, M. E. et al., Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone. Neurology 2003, 61, 783-791.
34. Holman, R. C., Khan, A. S., Belay, E. D., Schonberger, L. B., Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg. Infect. Dis. 1996, 2, 333-337.
35. Billette de Villemeur, T., Deslys, J. P., Pradel, A., Soubrié, C. et al., Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology 1996, 47, 690-695.
36. Croes, E. A., Roks, G., Jansen, G. H., Nijssen, P. C. et al., Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone. J Neurol Neurosurg Psychiatry 2002, 72, 792-793.
37. Cochius, J. I., Burns, R. J., Blumbergs, P. C., Mack, K. et al., Creutzfeldt-Jakob disease in a recipient of human pituitaryderived gonadotrophin. Aust NZ J Med. 1990, 20, 592-593.
38. Dumble, L. J., Klein, R. D., Creutzfeld-Jacob disease legacy for Australian women treated with human pituitary gonadotropins. Lancet 1992, 340, 847-848.
39. Morens, D. M., Folkers, G. K., Fauci, A. S., The challenge of emerging and re-emerging infectious diseases. Nature 2004, 430, 242-249.
40. Beisel, C. E., Morens, D. M., Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies. Clin Infect Dis. 2004, 38, 697-704.
41. Xie, Z., O'Rourke, K. I., Dong, Z., Jenny, A. L. et al., Chronic wasting disease of elk and deer and Creutzfeldt-Jakob disease: comparative analysis of the scrapie prion protein. J Biol Chem. 2006, 281, 4199-4206.
42. Anderson, C. A., Bosque, P., Filley, C. M., Arciniegas, D. B. et al., Colorado surveillance program for chronic wasting disease transmission to humans: lessons from 2 highly suspicious but negative cases. Arch Neurol. 2007, 64, 439-441.
43. Busch, M. P., Kleinman, S. H., Nemo, G. J., Current and emerging infectious risks of blood transfusions. JAMA 2003, 289, 959-962.
44. Stein, A., Decreasing variability in your cell culture. Biotechniques 2007, 43, 228-229.
45. Froud, S. J., The development, benefits and disadvantages of serum-free media. Dev Biol Stand. 1999, 99, 157-166
46. Butler, M., Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol. 2005, 68, 283-291.
47. Zhou, J. X., Tressel, T., Yang, X., Seewoester, T., Implementation of advanced technologies in commercial monoclonal antibody production. Biotechnol J. 2008, Aug 29.
48. Merten, O. W., Development of serum-free media for cell growth and production of viruses/viral vaccines - safety issues of animal products used in serum-free media. Dev Biol (Basel). 2002, 111, 233-257.
49. Keenan, J., Pearson, D., Clynes, M., The role of recombinant proteins in the development of serum-free media. Cytotechnology 2006, 50, 49-56.
50. Sunstrom, N. A., Gay, R. D., Wong, D. C., Kitchen, N. A. et al., Insulin-like growth factor-I and transferrin mediate growth and survival of Chinese hamster ovary cells. Biotechnol Prog. 2000, 16, 698-702.
51. Kaufman, R. J., Wasley, L.C., Davies, M.V., Wise, R. J. et al., Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol. 1989, 9, 1233-1242.
52. Erstad, B. L., Viral infectivity of albumin and plasma protein fraction. Pharmacotherapy 1996, 16, 996-1001.
53. Peters, T. J., The albumin molecule: its structure and chemical properties, in: All About Albumin: Biochemistry, Genetics and Medical Applications. San Diego: Academic Press 1996, pp. 9-75.
54. Berezenko, S., Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med. 2006, 34, 1291.
55. Tarelli, E., Mire-Sluis, A., Tivnann, H. A., Bolgiano, B. et al., Recombinant human albumin as a stabilizer for biological materials and for the preparation of international reference reagents. Biologicals 1998, 26, 331-346.
56. Thyagarajapuram, N., Olsen, D., Middaugh, C. R., Stabilization of proteins by recombinant human gelatins. J Pharm Sci. 2007, 96, 3304-3315.
57. Thyagarajapuram, N., Olsen, D., Middaugh, C. R., The structure, stability, and complex behavior of recombinant human gelatins. J Pharm Sci. 2007, 96, 3363-3378.
58. Hermeling, S., Crommelin, D. J., Schellekens, H., Jiskoot, W., Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004, 21, 897-903.
59. Maas, C., Hermeling, S., Bouma, B., Jiskoot, W. et al., A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem. 2007, 282, 2229-2236
60. Hermeling, S., Schellekens, H., Maas, C., Gebbink, M.F. et al., Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 2006, 95, 1084-1096.
61. Ruiz, L., Reyes, N., Duany, L., Franco A. et al., Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. Int J Pharm. 2003, 264, 57-72.
62. Jaber, A., Driebergen, R., Giovannoni, G., Schellekens, H. et al., The Rebif new formulation story: it's not trials and error. Drugs R D. 2007, 8, 335-348.
63. Giovannoni, G., Barbarash, O., Casset-Semanaz, F., King, J. et al., Safety and immunogenicity of a new formulation of interferon â1a (Rebif(R) New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2008, Aug 28.
64. Pavlou, A. K., Belsey, M. J., The therapeutic antibodies market to 2008. Eur J Pharm Biopharm. 2005, 59, 389-396.
65. Morrow, K. J. Jr. Advances in antibody manufacturing using mammalian cells. Biotechnol Annu Rev. 2007, 13, 95-113.
66. Merten, O. W., Safety issues of animal products used in serum-free media. Dev Biol Stand. 1999, 99, 167-180.
67. Even, M. S., Sandusky, C. B., Barnard, N. D., Serum-free hybridoma culture: ethical, scientific and safety considerations. Trends Biotechnol. 2006, 24, 105-108.
68. Dolan, G., Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience. Haemophilia 2006, 12(suppl 1), 16-20.
69. Valentino, L. A., Oza, V. M., Blood safety and the choice of anti-hemophilic factor concentrate. Pediatr Blood Cancer 2006, 47, 245-254.
70. Dodd, R.Y., Current risk for transfusion transmitted infections. Curr Opin Hematol. 2007, 14, 671-676.
71. Wroe, S. J., Pal, S., Siddique, D., Hyare, H. et al., Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006, 368, 2061-2067.
72. Pipe, S., Consideration in hemophilia therapy selection. Semin Hematol. 2006, 43 (2 Suppl 3), S23-27.
73. Evatt, B., Infectious disease in the blood supply and the public health response. Semin Hematol. 2006, 43 (2 Suppl 3), S4-9.
74. EMEA, Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMEA/410/01. Rev2, adopted July 2004). Official Journal of the European Union, http://www.emea.europa.eu/pdfs/human/bwp/ TSE%20NFG%20410-rev2.pdf
75. CPMP, Core SPC for human plasma derived and recombinant coagulation factor VIII products. 2000, June 29, 1-7, http://www.emea.europa.eu/pdfs/ human/bpwg/161999en.pdf
76. NHF, MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders. MASAC recommendation #182, 2008, April, http://www.hemophilia.org
77. Keeling, D., Tait, C., Makris, M., Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2008, 14, 671-684.
78. CHS, CHS Policy on Blood, Blood Products and their Alternatives. 2003, May 15, http://www.hemophilia.ca/en/1.2.1.php
79. FDA, Points to consider in the characterization of cell lines used to produce biologicals. 1993, July 12, http://www.fda.gov/CBER/gdlns/ ptccell.pdf
80. FDA, Guidance for Industry. Characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. 2006-Draft, http://www.fda.gov/Cber/gdlns/ vaccsubstrates.pdf
81. ICH, Q5A(R1): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. 1997, March, http://www.ich.org/LOB/media/MEDIA425.pdf
82. ICH, Q5D: Derivation and characterisation of cell substrates used for production of biotechnological/biological products. 1997, July, http://www.ich.org/LOB/media/MEDIA429.pdf
83. Heneine, W., Switzer, W. M., Soucie, J. M., Evatt, B. L. et al., Evidence of porcine endogenous retroviruses in porcine factor VIII and evaluation of transmission to recipients with hemophilia. J Infect Dis. 2001, 183, 648-652.
84. Cournoyer, D., Toffelmire, E. B., Wells, G. A., Barber, D. L. et al., Canadian PRCA Focus Group. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol. 2004, 15, 2728-2734.
85. Eckardt, K. U., Casadevall, N., Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant. 2003, 18, 865-869.
86. Serrato, J. A., Hernández, V., Estrada-Mondaca, S., Palomares, L.A. et al., Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum-supplemented, serum-free or chemically defined media. Biotechnol Appl Biochem. 2007, 47(Pt 2), 113-124.
87. Anonymous, Abseamed - European Public Assessment Report (Scientific Discussion) 2007, http://www.emea.europa.eu/humandocs/PDFs/EPAR/abseamed/ H-727-en6.pdf
88. Wang, S. S., Wu, J.W., Yamamoto, S., Liu, H. S., Diseases of protein aggregation and the hunt for potential pharmacological agents. Biotechnol J. 2008, 3, 165-192.